Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Vaccine's Department, Centre of Molecular Immunology, 216 esq 15, Atabey, Playa, CP 16040, C. Habana, Cuba. circe@ict.cim.sld.cu
The development of potent adjuvants, conditioning innate and adaptative immunity, particularly CTL responses, has become currently a hot point in the rational design of vaccines for cancer immunotherapy. We have described a new approach, in which gangliosides are incorporated into vesicles from Neisseria meningitidis to form Very Small Size Proteoliposomes (VSSP). VSSP is a good alternative to the existing adjuvants for use in whole cells vaccines since it promotes 80% tumour rejection and growing delay in the CT26 and F3II tumour models respectively. Also VSSP induces activation of CTL responses to co-injected trimmed peptides and soluble proteins. This phenomena is facilitated by the cross-presentation of exogenous antigen and do not need cooperation of CD4 T cells for primary CD8 T cells expansion.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on